Endothelin-1 and endothelin-2 initiate and maintain contractile responses by different mechanisms in rat mesenteric and cerebral arteries

British Journal of Pharmacology

Volumn 170, Issue 6, 2013, Pages 1199-1209

  Compeer, M G ^a   Janssen, G M J ^a   De Mey, J G R ^a,b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

basilar artery; endothelin 1; endothelin 2; ETA receptors; mesenteric resistance artery; PLC; RhoK; vascular smooth muscle; vasoconstrictions; vasospasms

Indexed keywords

ENDOTHELIN 1; ENDOTHELIN 2; PHOSPHOLIPASE C;

ANIMAL TISSUE; ARTERY CONSTRICTION; ARTERY RESISTANCE; ARTICLE; BASILAR ARTERY; CONTROLLED STUDY; ENZYME ACTIVITY; MALE; MESENTERIC ARTERY; MESENTERIC RESISTANCE ARTERY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; VASOCONSTRICTION; VASOMOTOR REFLEX;

BASILAR ARTERY; ENDOTHELIN-1; ENDOTHELIN-2; ETA RECEPTORS; MESENTERIC RESISTANCE ARTERY; PLC; RHOK; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTIONS; VASOSPASMS;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANIMALS; CEREBRAL ARTERIES; ENDOTHELIN-1; ENDOTHELIN-2; ESTRENES; MALE; MESENTERIC ARTERIES; PHOSPHODIESTERASE INHIBITORS; PROTEIN KINASE INHIBITORS; PYRROLIDINONES; RATS; RATS, INBRED WKY; RHO-ASSOCIATED KINASES; TYPE C PHOSPHOLIPASES; VASOCONSTRICTION;

EID: 84886796389     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12332     Document Type: Article

References (60)

1. Adner M, Shankley N, Edvinsson L, (2001). Evidence that ET-1, but not ET-3 and S6b, ET(A)-receptor mediated contractions in isolated rat mesenteric arteries are modulated by co-activation of ET(B) receptors. Br J Pharmacol 133: 927-935.
2. Alexander SP, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th edition. Br J Pharmacol 164 (Suppl. 1): S1-324.
3. Aviado DM, Jr, Wnuck AL, De Beer EJ, (1958). Cardiovascular effects of sympathomimetic bronchodilators; epinephrine, ephedrine, pseudoephedrine, isoproterenol, methoxyphenamine and isoprophenamine. J Pharmacol Exp Ther 122: 406-417.
4. Badr KF, Murray JJ, Breyer MD, Takahashi K, Inagami T, Harris RC, (1989). Mesangial cell, glomerular and renal vascular responses to endothelin in the rat kidney. Elucidation of signal transduction pathways. J Clin Invest 83: 336-342.
5. Bleasdale JE, Thakur NR, Gremban RS, Bundy GL, Fitzpatrick FA, Smith RJ, et al. (1990). Selective inhibition of receptor-coupled phospholipase C-dependent processes in human platelets and polymorphonuclear neutrophils. J Pharmacol Exp Ther 255: 756-768.
6. Boonen HC, De Mey JG, (1990). G-proteins are involved in contractile responses of isolated mesenteric resistance arteries to agonists. Naunyn Schmiedebergs Arch Pharmacol 342: 462-468.
7. Buther K, Compeer MG, De Mey JG, Schober O, Schafers M, Bremer C, et al. (2012). Assessment of endothelin-A receptor expression in subcutaneous and orthotopic thyroid carcinoma xenografts in vivo employing optical imaging methods. Endocrinology 153: 2907-2918.
8. Carlsen JE, Kardel T, Jensen HA, Tango M, Trap-Jensen J, (1983). Pinacidil, a new vasodilator: pharmacokinetics and pharmacodynamics of a new retarded release tablet in essential hypertension. Eur J Clin Pharmacol 25: 557-561.
9. Christopoulos A, May LT, Avlani VA, Sexton PM, (2004). G-protein-coupled receptor allosterism: the promise and the problem(s). Biochem Soc Trans 32 (Pt 5): 873-877.
10. Clarke CJ, Forman S, Pritchett J, Ohanian V, Ohanian J, (2008). Phospholipase C-delta1 modulates sustained contraction of rat mesenteric small arteries in response to noradrenaline, but not endothelin-1. Am J Physiol Heart Circ Physiol 295: H826-H834.
11. Compeer MG, Meens MJ, Hackeng TM, Neugebauer WA, Holtke C, De Mey JG, (2012a). Agonist-dependent modulation of arterial endothelinA receptor function. Br J Pharmacol 166: 1833-1845.
12. Compeer MG, Suylen DP, Hackeng TM, De Mey JG, (2012b). Endothelin-1 and -2: two amino acids matter. Life Sci 91: 607-612.
13. Davenport AP, (2002). International Union of Pharmacology. XXIX. Update on endothelin receptor nomenclature. Pharmacol Rev 54: 219-226.
14. De Mey JG, Claeys M, Vanhoutte PM, (1982). Endothelium-dependent inhibitory effects of acetylcholine, adenosine triphosphate, thrombin and arachidonic acid in the canine femoral artery. J Pharmacol Exp Ther 222: 166-173.
15. De Mey JG, Megens R, Fazzi GE, (2008). Functional antagonism between endogenous neuropeptide Y and calcitonin gene-related peptide in mesenteric resistance arteries. J Pharmacol Exp Ther 324: 930-937.
16. De Mey JG, Compeer MG, Lemkens P, Meens MJ, (2011). ETA-receptor antagonists or allosteric modulators? Trends Pharmacol Sci 32: 345-351.
17. Elmarakby AA, Loomis ED, Pollock JS, Pollock DM, (2005). NADPH oxidase inhibition attenuates oxidative stress but not hypertension produced by chronic ET-1. Hypertension 45: 283-287.
18. Evgenov OV, Pacher P, Schmidt PM, Hasko G, Schmidt HH, Stasch JP, (2006). NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 5: 755-768.
19. Harteneck C, Gollasch M, (2011). Pharmacological modulation of diacylglycerol-sensitive TRPC3/6/7 channels. Curr Pharm Biotechnol 12: 35-41.
20. Herlitz H, Aurell M, Conradson T, (1983). Felodipine, an arteriolar dilator with pronounced antihypertensive effect. Lancet 1: 409-410.
21. Hilal-Dandan R, Villegas S, Gonzalez A, Brunton LL, (1997). The quasi-irreversible nature of endothelin binding and G protein-linked signaling in cardiac myocytes. J Pharmacol Exp Ther 281: 267-273.
22. Hirata Y, Emori T, Eguchi S, Kanno K, Imai T, Ohta K, et al. (1993). Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest 91: 1367-1373.
23. Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K, et al. (1989). The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A 86: 2863-2867.
24. Kandabashi T, Shimokawa H, Mukai Y, Matoba T, Kunihiro I, Morikawa K, et al. (2002). Involvement of rho-kinase in agonists-induced contractions of arteriosclerotic human arteries. Arterioscler Thromb Vasc Biol 22: 243-248.
25. Kawasaki T, Ueyama T, Lange I, Feske S, Saito N, (2010). Protein kinase C-induced phosphorylation of Orai1 regulates the intracellular Ca2+ level via the store-operated Ca2+ channel. J Biol Chem 285: 25720-25730.
26. Kenakin T, Miller LJ, (2010). Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev 62: 265-304.
27. Keov P, Sexton PM, Christopoulos A, (2011). Allosteric modulation of G protein-coupled receptors: a pharmacological perspective. Neuropharmacology 60: 24-35.
28. Khodorova A, Montmayeur JP, Strichartz G, (2009). Endothelin receptors and pain. J Pain 10: 4-28.
29. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: Reporting in vivo experiments: The ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
30. Kirkby NS, Hadoke PW, Bagnall AJ, Webb DJ, (2008). The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br J Pharmacol 153: 1105-1119.
31. Kiyonaka S, Kato K, Nishida M, Mio K, Numaga T, Sawaguchi Y, et al. (2009). Selective and direct inhibition of TRPC3 channels underlies biological activities of a pyrazole compound. Proc Natl Acad Sci U S A 106: 5400-5405.
32. Klein RR, Bourdon DM, Costales CL, Wagner CD, White WL, Williams JD, et al. (2011). Direct activation of human phospholipase C by its well known inhibitor u73122. J Biol Chem 286: 12407-12416.
33. Kohan DE, Cleland JG, Rubin LJ, Theodorescu D, Barton M, (2012). Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve? Life Sci 91: 528-539.
34. Ling L, Maguire JJ, Davenport AP, (2013). Endothelin-2, the forgotten isoform: emerging role in the cardiovascular system, ovarian development, immunology and cancer. Br J Pharmacol 168: 283-295.
35. Loirand G, Guerin P, Pacaud P, (2006). Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 98: 322-334.
36. Masaki T, (2004). Historical review: endothelin. Trends Pharmacol Sci 25: 219-224.
37. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
38. Meens MJ, Fazzi GE, van Zandvoort MA, De Mey JG, (2009). Calcitonin gene-related peptide selectively relaxes contractile responses to endothelin-1 in rat mesenteric resistance arteries. J Pharmacol Exp Ther 331: 87-95.
39. Meens MJ, Compeer MG, Hackeng TM, van Zandvoort MA, Janssen BJ, De Mey JG, (2010). Stimuli of sensory-motor nerves terminate arterial contractile effects of endothelin-1 by CGRP and dissociation of ET-1/ET(A)-receptor complexes. PLoS ONE 5: e10917.
40. Meens MJ, Mattheij NJ, Nelissen J, Lemkens P, Compeer MG, Janssen BJ, et al. (2011). Calcitonin gene-related peptide terminates long-lasting vasopressor responses to endothelin 1 in vivo. Hypertension 58: 99-106.
41. Meens MJ, Mattheij NJ, van Loenen PB, Spijkers LJ, Lemkens P, Nelissen J, et al. (2012). G-protein betagamma subunits in vasorelaxing and anti-endothelinergic effects of calcitonin gene-related peptide. Br J Pharmacol 166: 297-308.
42. Morel N, Godfraind T, (1988). Selective modulation by membrane potential of the interaction of some calcium entry blockers with calcium channels in rat mesenteric artery. Br J Pharmacol 95: 252-258.
43. Morris GE, Nelson CP, Standen NB, Challiss RA, Willets JM, (2010). Endothelin signalling in arterial smooth muscle is tightly regulated by G protein-coupled receptor kinase 2. Cardiovasc Res 85: 424-433.
44. Neylon CB, (1999). Vascular biology of endothelin signal transduction. Clin Exp Pharmacol Physiol 26: 149-153.
45. Pankey EA, Bhartiya M, Badejo AM, Jr, Haider U, Stasch JP, Murthy SN, et al. (2011). Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase activator, BAY 60-2770, are not dependent on endogenous nitric oxide or reduced heme. Am J Physiol Heart Circ Physiol 300: H792-H802.
46. Pulcinelli FM, Gresele P, Bonuglia M, Gazzaniga PP, (1998). Evidence for separate effects of U73122 on phospholipase C and calcium channels in human platelets. Biochem Pharmacol 56: 1481-1484.
47. Rizzoni D, Porteri E, Piccoli A, Castellano M, Bettoni G, Pasini G, et al. (1997). The vasoconstriction induced by endothelin-1 is mediated only by ET(A) receptors in mesenteric small resistance arteries of spontaneously hypertensive rats and Wistar Kyoto rats. J Hypertens 15 (12 Pt 2): 1653-1657.
48. Saleh SN, Albert AP, Large WA, (2009). Activation of native TRPC1/C5/C6 channels by endothelin-1 is mediated by both PIP3 and PIP2 in rabbit coronary artery myocytes. J Physiol 587 (Pt 22): 5361-5375.
49. Schleifer H, Doleschal B, Lichtenegger M, Oppenrieder R, Derler I, Frischauf I, et al. (2012). Novel pyrazole compounds for pharmacological discrimination between receptor-operated and store-operated Ca(2+) entry pathways. Br J Pharmacol 167: 1712-1722.
50. Schneider MP, Boesen EI, Pollock DM, (2007). Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease. Annu Rev Pharmacol Toxicol 47: 731-759.
51. Seamon KB, Padgett W, Daly JW, (1981). Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells. Proc Natl Acad Sci U S A 78: 3363-3367.
52. Somlyo AP, Somlyo AV, (2000). Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. J Physiol 522 (Pt 2): 177-185.
53. Stasch JP, Becker EM, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, et al. (2001). NO-independent regulatory site on soluble guanylate cyclase. Nature 410: 212-215.
54. Vazquez G, Tano JY, Smedlund K, (2010). On the potential role of source and species of diacylglycerol in phospholipase-dependent regulation of TRPC3 channels. Channels (Austin) 4: 232-240.
55. Wagner OF, Vierhapper H, Gasic S, Nowotny P, Waldhausl W, (1992). Regional effects and clearance of endothelin-1 across pulmonary and splanchnic circulation. Eur J Clin Invest 22: 277-282.
56. Wang Y, Wang DH, (2004). Prevention of endothelin-1-induced increases in blood pressure: role of endogenous CGRP. Am J Physiol Heart Circ Physiol 287: H1868-H1874.
57. Warner TD, Mitchell JA, de Nucci G, Vane JR, (1989). Endothelin-1 and endothelin-3 release EDRF from isolated perfused arterial vessels of the rat and rabbit. J Cardiovasc Pharmacol 13 (Suppl. 5): S85-S88; discussion S102.
58. Wynne BM, Chiao CW, Webb RC, (2009). Vascular smooth muscle cell signaling mechanisms for contraction to angiotensin II and endothelin-1. J Am Soc Hypertens 3: 84-95.
59. Xie A, Aihara Y, Bouryi VA, Nikitina E, Jahromi BS, Zhang ZD, et al. (2007). Novel mechanism of endothelin-1-induced vasospasm after subarachnoid hemorrhage. J Cereb Blood Flow Metab 27: 1692-1701.
60. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. (1988). A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 411-415.